Related Experiment Video
Updated: Feb 14, 2026
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
16.3K
B-cell targeting in chronic graft-versus-host disease
Robert Zeiser1, Stefanie Sarantopoulos2, Bruce R Blazar3
1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University, Freiburg, Germany.
Blood
|February 14, 2018
Summary
Chronic graft-versus-host disease (cGVHD) involves B cells. Emerging research highlights B cell pathophysiology and novel therapies targeting these cells for improved treatment strategies.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic stem cell transplantation.
- Recent advancements have improved understanding of cGVHD pathophysiology.
- B cells play a critical role in the development and progression of cGVHD.
Purpose of the Study:
- To review current knowledge on the pathophysiology of cGVHD, emphasizing the role of B cells.
- To discuss emerging B cell-targeted therapies for cGVHD.
- To provide clinicians with an overview of novel therapeutic strategies for cGVHD.
Main Methods:
- Review of preclinical (mouse) and clinical (human) studies.
- Analysis of evidence supporting B cell involvement in cGVHD.
- Synthesis of data on novel B cell-targeting agents.
Main Results:
- Evidence from mouse and human studies implicates B cells in cGVHD pathogenesis.
- Several novel therapeutic approaches targeting B cells are under investigation.
- These therapies offer potential new avenues for managing cGVHD.
Conclusions:
- B cells are key players in the pathophysiology of chronic graft-versus-host disease.
- Targeting B cells represents a promising therapeutic strategy for cGVHD.
- Further research and clinical trials are needed to validate these novel approaches.
More Related Videos
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
01:25Chronic Kidney Disease I: Introduction
780
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
780
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:24Chronic Kidney Disease II: Clinical Manifestations
700
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
700
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.8K